The non-cystic fibrosis bronchiectasis market is driven by rising prevalence linked to respiratory infections, autoimmune diseases, and COPD. Increasing awareness among healthcare providers and ...
"We are particularly excited about the single-cell transcriptomics database we're building with Boehringer Ingelheim to drive research and ... insights across Alexion's Research & Development, ...
“We are particularly excited about the single-cell transcriptomics database we’re building with Boehringer Ingelheim to drive research and ... insights across Alexion’s Research & Development, ...
Kikuchi–Fujimoto disease (KFD), histiocytic necrotising lymphadenitis, is a benign and self-limiting disease characterised ...
Exacerbations of the chronic and progressive inflammatory disease bronchiectasis can impact quality of life. Treatment, based ...
No. 49 / 2024Zealand Pharma Announces Financial Results for the First Nine Months of 2024Continued strong progress across ...
Substantial enrollment progress in Phase 1b trial of SZN-043 in severe alcohol-associated hepatitis patients with proof-of-concept data expected ...
Danish biotech Gubra announces that Germany’s Boehringer Ingelheim has decided to discontinue the development of the long-acting neuropeptide Y receptor type 2 (NPY2R) agonist BI 1820237 in obesity.
Privately-held German drugmaker Boehringer Ingelheim and researchers from the Stanley Center for Psychiatric Research at the ...
The National Turkey Federation supports import permit to improve treatment of the contagious respiratory disease.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback